The Biotechnology Innovation Organization and two California-based biotech trade groups filed suit to block a US Medicare demonstration that would align drug prices with “peer countries.” The complaint, filed in the Northern District of California, alleges the program—known as the Global Benchmark for Efficient Drug Pricing (GLOBE)—exceeds Medicare’s statutory authority. The action signals renewed legal pressure on US pricing models as payor-side benchmarking approaches move from policy proposals toward operational enforcement. The outcome could directly affect launch strategies, negotiation dynamics, and forecasting for high-cost biologics and gene therapies.